Arena Pharmaceuticals, Inc. (ARNA) came out with a quarterly loss of $2.40 per share versus the Zacks Consensus Estimate of a loss of $2.21. This compares to loss of $1.61 per share a year ago. These ...

Insiders who purchased Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) shares in the past 12 months are unlikely to be deeply impacted by the stock's 6.9% decline over the past week. After taking the recent ...

Amit Munshi has been President and Chief Executive Officer of Arena Pharmaceuticals (ARNA) since May 2016 and has been a member of the board of directors since June 2016. Previously, Mr. Munshi was ...

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) was in 13 hedge funds’ portfolio at the end of the first quarter of 2013. ARNA investors should pay attention to an increase in support from the world’s most ...

What: Shares of Arena Pharmaceuticals, a biopharmaceutical company primarily focused on developing therapies for weight management and to treat autoimmune diseases, jumped 24% in January per S&P ...

PARK CITY, Utah--(BUSINESS WIRE)-- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced they will be hosting two virtual R&D Investor calls for analysts and investors focused on the Company’s ...

Out of thousands of stocks that are currently traded on the market, it is difficult to identify those that will really generate strong returns. Hedge funds and institutional investors spend millions ...

The top analyst upgrades, downgrades and initiations seen on Thursday included Arena Pharmaceuticals, Autodesk, Coca-Cola, General Electric, Marvell, Monster Beverages, Nabors and Procter & Gamble.

PARK CITY, Utah--(BUSINESS WIRE)--Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced they will be hosting two virtual R&D Investor calls for analysts and investors focused on the Company’s ...